Evaluation of Two Commercially Available DNA Tests for Detection of Human Papillomavirus

Diane C. Halstead, Sharon L.H. Pfleger, and William Dupree
Microbiology/Virology Division (D.C.H.), Pathology Department (W.D.), Lehigh Valley Hospital, Allentown, PA, and Microbiology Division (S.L.H.P.), Warren Hospital, Phillipsburg, NJ

ABSTRACT

Objective: This study was designed to compare the sensitivity, specificity, efficiency, positive and negative predictive values, and ease of use for 2 commercially available hybridization kits for detecting human papillomavirus (HPV) DNA: Oncor Southern blot (SB) (Oncor, Inc., Gaithersburg, MD) and Digene ViraType dot blot (DB) (Digene Diagnostics, Inc., Silver Spring, MD).

Methods: A total of 179 specimens (172 cervical and 7 penile biopsies) were assessed for acceptability based on the presence of epithelial cells and tested for HPV by DB and SB. The results were evaluated based on Papanicolaou-stained cervical specimens and selected risk factors.

Results: One hundred six (97.2%) of 109 results were concordant, i.e., 93 negative (85.3%) and 13 positive (11.9%). Using SB as the gold standard, we found the sensitivity, specificity, efficiency, and positive and negative predictive values for the ViraType DB to be 100%, 96.9%, 97.3%, 81.3%, and 100%, respectively. Comparing the Papanicolaou smear to SB and DB, we found the sensitivity, specificity, efficiency, and positive and negative predictive values to be 33.3% (SB) vs. 44.4% (DB), 89.5% vs. 87.6%, 87.3% vs. 84.2%, 11.8% vs. 23.5%, and 97.0% vs. 94.9%, respectively. The only significant risk factor for predicting an HPV infection was the number of sexual partners.

Conclusions: Although SB has been considered the standard model, DB is an acceptable method for detecting and identifying HPV infections.

KEY WORDS
Papillomavirus DNA, hybridization kits, HPV infection, Papanicolaou smear, SIL
Further confounding the issue is the fact that statements in regard to the natural history of SILs are based on population statistics. Hence, the individual patient and her physician are faced with a probability statement as to what her unique course might be. What is needed is a means to determine which individual low-grade SILs will progress or persist and which will regress.

Although unequivocal evidence establishing that human papillomavirus (HPV) alone is the cause of cervical cancer and its precursor lesions is lacking, the strong association between HPV infection and these disease processes spurs intense efforts to better define the pathogenetic role of HPV. Of >70 different types of HPV that infect humans, >20 have a predilection for the genital tract. These can be divided into 3 groups: those with little or no oncogenic risk, those with an intermediate oncogenic risk, and those with a high oncogenic risk. Based on a stratification of HPV types into oncogenic risk groups, Reid and Lorincz have suggested that determining which patients with low-grade SIL will require treatment and which may be followed should be based in part on the use of HPV typing. These authors suggested that the patients whose lesions were associated with low-oncogenic-risk viral types might require neither therapy nor close clinical follow-up, whereas those lesions associated with high-oncogenic-risk HPV types should be treated “appropriately.” Lesions with intermediate oncogenic viral types could be closely followed prospectively. Apart from the potential benefits for the patient, in an era of medical cost containment, this type of triage protocol has great appeal.

One of the problems associated with this triage strategy has centered around the reported insensitivity of commercially available HPV typing. This study was designed to compare the sensitivity, specificity, efficiency, positive and negative predictive values, and the ease of use for 2 commercially available hybridization kits: Oncor Southern blot (SB) (Oncor, Inc., Gaithersburg, MD) and Digene ViraType dot blot (DB) (Digene Diagnostics, Inc., Silver Spring, MD). These kits utilize biotinylated and 32P-labeled RNA probes, respectively. The results from these 2 methods were correlated with cytology findings and patient risk factors.

Subjects and Methods

Specimens
A double-blind coded study was performed on a total of 179 genital specimens collected between May 1991 and February 1992. There were 172 cervical specimens, including 146 from a private physician’s office and 26 from the Lehigh Valley Hospital OB/GYN clinic, and 7 penile biopsies from condylomatous lesions collected in an ambulatory surgical unit. The women were asked to sign consent forms and to complete questionnaires in order to assess their risk factors and clinical histories. The following information was obtained from the questionnaire: age at first sexual encounter, number of sexual partners, use of barrier protection, previous sexually transmitted disease(s), abnormal Papanicolaou smear(s), previous gynecological infections, family history of neoplastic disease, and compromised immune system.

Specimen Collection and Processing
Exfoliated cervical cells were collected using a sterile Christmas-tree cytobrush (Cat. #CYB, Medical Packaging Corp., Camarillo, CA). Three sequential cervical specimens were collected under direct visualization. A smear for Papanicolaou staining was prepared from the first cervical specimen. The remaining 2 specimens were placed in Digene transport medium (Digene Diagnostics, Inc.) and refrigerated for not more than 2 weeks, coded, evaluated for adequacy, and frozen at −70°C before processing. The biopsy specimens were hand-delivered to the laboratory in sterile tubes, coded, and frozen in phosphate-buffered saline at −70°C before processing.

The Papanicolaou smears were reviewed by a member of the cytology staff and a cytopathologist in accordance with the Bethesda System of nomenclature. The results obtained from the smears were placed into 7 categories for data analysis as follows: 1) normal; 2) infection, not HPV, bacteria/fungi; 3) inflammation with associated cell changes; 4) squamous atypia of undetermined significance, suggest repeat; 5) SIL-L (CIN I), condylomas, hyperkeratosis or parakeratosis suggestive of HPV, or koilocytes; 6) SIL-H (CIN II, CIN III), carcinoma in situ (CIS); and 7) unacceptable. The previous cytology results were also noted.
Each pair of specimens in transport medium was vortexed prior to removal of the cytobrushes, combined, and tested for adequacy by counting the number of squamous and columnar epithelial cells/low-power microscope field (lpf) in a wet-mount preparation. A specimen was considered adequate if at least an occasional cell (>1 cell/lpf) was observed. Using the established criteria, we found 167/172 (97.1%) cervical specimens to be acceptable. The results were not available for 3/5 remaining specimens; 2 specimens were unacceptable. The presence of blood was also noted. The combined specimens were evenly distributed between 2 tubes (approximately 1 ml each) and frozen at −70°C until tested.

**Oncor SB Procedure**

The specimens were tested according to the manufacturer's directions (Oncor, Inc.) using the Oncor Probe Tech automated electrophoresis instrument. The Oncor kit included “antisense” biotinylated probes with nucleic-acid sequences complementary to the entire viral genome of HPV types 6, 11, 16, 31, 33, and 35 and E6/E7 early open-reading frame (ORF) and L1 late ORF of HPV 18.

The results were interpreted according to the criteria established by Oncor. High and low concentration controls were used to identify the HPV-type specific bands. The procedure allows the identification of types 6, 11, 16, 18, 31, 33, and 35. If a sample did not form a band consistent with one of these HPV types, it was recorded as an “other” HPV type.

**Digene ViraType DB Procedure**

The ViraType kit was obtained from Digene Diagnostics, Inc. The kit includes 32P-labeled RNA probes for the detection of HPV groups 6/11, 16/18, and 31/33/35. The probes are prepared by in vitro transcription of recombinant plasmid containing nearly the entire DNA sequences of HPV. With the exception of 2 specimens, visibly bloody specimens were not tested, according to the manufacturer's recommendations.

To determine the HPV type in a specimen, we compared the autoradiographic signal that was generated by the specimen with the positive control for the corresponding HPV probe group. Any signal greater than the negative control was considered positive. To distinguish between infection with a single type and one with multiple types, we compared the signals obtained with each positive patient blot and control. If the test specimen gave an autoradiographic signal with only one probe, the specimen was scored positive for that group of HPV types, e.g., 16/18. If the same specimen also exhibited a signal with another probe, e.g., 31/33/35, which was less than or equal to the signal produced by the 16/18 positive control on the membrane with the 31/33/35 probe, the specimen was scored negative for 31/33/35. If the test specimen gave a positive signal that was greater than the 16/18 positive control, a multiple infection could not be ruled out.

**Statistical Analysis**

The statistical significance of the SB and DB results was determined using Youden's square. Contingency tables were used to analyze the risk factors and cytology results.

**RESULTS**

**Correlation of SB and DB**

One hundred seventy-nine specimens (172 cervical specimens from females between the ages of 13 and 77 years and 7 penile biopsies) were collected for HPV typing. A total of 109 specimens (102 cervical scrapings and 7 penile biopsies) were tested by both SB and DB. Seventy additional specimens were tested by either SB (54) or DB (16). Fifty-four of the 172 cervical specimens were visibly bloody and were not tested by DB because, according to the manufacturer's directions, bloody specimens may produce false negative results. Sixteen additional specimens were only tested by ViraType.

Sixteen (14.7%) of the specimens (9 cervical and all 7 biopsies) were positive by either SB or DB. Complete concordance between SB and DB assays was obtained with 106/109 (97.3%) specimens: 93/106 (87.7%) negative and 13/106 (12.3%) positive results. Three discordant specimens were positive by DB and negative by SB (Fig. 1). Using SB as the gold standard, we found the DB method to have sensitivity, specificity, efficiency, and positive and negative predictive values of 100%, 96.9%, 97.3%, 81.3%, and 100%, respectively ($P = 0.000$). All 7 penile biopsies were positive by both methods. Table 1 lists the HPV-type distribu-
EVALUATION OF TWO HPV TESTS

Fig. 1. Results of HPV nucleic-acid hybridization. Of a total of 179 specimens, 109 (102 cervical, 7 biopsies) were tested on both systems.

TABLE I. HPV-type distribution in concordant specimens

<table>
<thead>
<tr>
<th>HPV type</th>
<th>Total no.</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 11 16 18 31 33 35</td>
<td></td>
</tr>
<tr>
<td>Oncor SB</td>
<td>7 1 2 1 3 2 0 16</td>
</tr>
<tr>
<td>Digene DB</td>
<td>8 3 5 16</td>
</tr>
</tbody>
</table>

Results are given in number of positives.

Correlation With Biopsy Specimens

The histology results were available from cervical biopsy specimens collected on 21/172 patients participating in our study. Eight specimens were collected prior to enrollment in the study and 13 were collected after study completion. Ten of 21 patients were negative for HPV by hybridization and biopsy, while 1 biopsy specimen was positive both histologically and by SB (type 18) and DB (type 16/18). Eight of 21 patients had biopsy specimens with condylomatous changes and/or koilocytosis, but were negative for HPV by hybridization. One of these specimens, however, tested positive for HPV using a chemiluminescent molecular hybridization assay (Hybrid Capture System, Digene Diagnostics, Inc.) during a subsequent evaluation in the author's laboratory. Two of 21 patients had positive SB and DB tests for type 6/11, but were biopsy negative.

Correlation of Risk Factors

Of the 7 potential risk factors for predicting HPV infection, only the number of lifetime partners was statistically significant in our study. Based on the logistic regression (Fig. 2) of the number of partners, the probability of acquiring HPV, with 1 partner considered the norm, is 0.017, increasing to 0.655 with 20 partners. The relative risk (Fig. 3) of acquiring HPV is 0.79 with 0 partners and 37.7 with 20 partners. For example, a person with 20 partners is 37 times more likely to become infected with HPV compared with a person with 1 partner. The relative odds risk (Fig. 4) of acquire-
Fig. 2. Using logistic regression, the probability of acquiring HPV, with 1 partner as the norm being 0.017 and increasing to 0.655 with 20 partners.

Fig. 3. Using 164 observations, the relative risk of acquiring HPV (0.79 with no partners and 37 times greater with 20 partners).

Fig. 4. Using 164 observations, the relative odds risk of acquiring HPV (106 times greater with 20 partners than with 1 partner).

**DISCUSSION**

Infection with papillomavirus is a rapidly growing sexually transmitted disease in the United States today. Because of its association with cervical carcinoma, the ability to detect HPV in genital specimens has become an important issue in the management of patients with equivocal Papanicolaou smears. Until recently, cytology has been the only means of detecting potential HPV infection. Several methods have been developed for use in the clinical laboratory in order to detect the presence of HPV in infected tissue as well as the HPV type including SB, DB, in situ hybridization, and more recently hybrid capture. In this evaluation, we compared the Oncor SB with the Digene DB technique to identify the presence of 7 of the most common HPV types (6, 11, 16, 18, 31, 33, and 35) in cervical specimens and penile biopsies collected from 179 patients. The SB method utilized biotinylated nucleic-acid RNA probes for the detection of the individual HPV types and the DB utilized 32P-labeled RNA probes for types 6/11, 16/18, and 31/33/35. The ViraType DB, rather than the ViraPap screening DB which utilizes a cocktail of the same probes, was chosen because the manufacturer stated that the ViraType was more sensitive. To date, reports comparing the results from these 2 kits have not been published. In addition, different risk factors and cytologic findings were assessed to further determine which group of individuals would most benefit from HPV testing.

SB hybridization is considered the gold standard for the identification of specific HPV types as well as the identification of new types and subtypes, although the SB procedure is technically challenging, labor intensive, and time-consuming, taking approximately 5 days to complete a batch of specimens. The Oncor procedure uses non-radiolabeled probes, which permits a long shelf life. Attention to detail and exact pipetting are required in order to obtain bands that are easily interpreted. The specimens collected in the Oncor transport medium must be stored at 4°C. The electrophoretic equipments' cost and technologist's time need to be considered when deciding to use SB vs. DB, although the
Oncor Probe Tech may be used for other molecular diagnostic tests such as gene rearrangement.

In contrast, the FDA-approved ViraType DB is relatively easy to perform and fast, being completed in 8 h, exclusive of autoradiography. The only equipment required are the manifolds and a vacuum pump. As a convenience, the specimens may be stored at room temperature for up to 2 weeks. A disadvantage of the DB method is the use of radiolabeled probes, with a shelf life of <2 weeks. As with the SB method, for cost effectiveness, specimens must be batched. According to the manufacturer's directions, bloody specimens may cause false negatives. False positives, on the other hand, may be caused by trapping of the probe by specimens containing significant protein and cellular debris. Unlike the SB, the ViraType DB only detects HPV groups 6/11, 16/18, and 31/33/35, rather than the individual types. However, the results may still provide the physician who wishes to test for HPV with information that can be used in patient management. An HPV-profile DB assay, which utilizes 2 probes (1 to identify low-risk HPV types 6, 11, 42, 43, and 44 and the other to detect intermediate and high-risk types 16, 18, 31, 33, 35, 45, 51, 52 and 56), is available for research use only (Digene Diagnostics, Inc.).

The specimens for HPV testing were collected with Christmas-tree cytobrushes at the same time the cytology smears were prepared in order to ensure that the cells were obtained from the same site. Each set of patient samples was combined, mixed, and reallocated to minimize sampling error. The collection of 3 specimens probably accounted for the high number of specimens with blood, i.e., 54/172 cervical specimens. Although Bartholoma et al. utilized bloody specimens in their evaluation of Oncor 32P-labeled probes vs. the Digene ViraPap 32P-labeled probes for HPV screening, they extracted and precipitated the DNA first. This procedure, however, was not endorsed by Digene (personal communication). Retrospectively, 2 visibly bloody SB-positive specimens were tested by DB; both were positive. Due to the current recommendation by many cytopathologists, cytobrushes were used to collect the specimens. Other studies have utilized swabs rather than brushes, which might have accounted for a report of decreased sensitivity of the SB compared with the DB procedure. Of the 109 specimens tested in parallel, 97.3% were concordant for the presence and type of HPV.

Of the 109 specimens tested in parallel, 97.3% were concordant for the presence and type of HPV. These findings are considerably higher than those of Burmer et al., Kiviat et al., and Bartholoma et al., who reported a concordance of 66% (102/154 specimens), 68% (62/91 specimens), and 78.7% (48/61 specimens), respectively. They also reported a higher number of positive specimens: 45/154 (29%), 91/450 (20%), and 31/61 (50.8%) specimens vs. 13/179 (7.3%) positive specimens obtained in this study. The low percent of positive specimens in this study probably reflects the patient population selected. In contrast to other studies, the majority of specimens (146/179) were obtained from patients seen in a private OB/GYN practice. In concordance with the findings of Bartholoma et al., all biopsies tested were DB and SB positive.

Kiviat et al. compared the ViraPap DB and SB using 32P-labeled probes. They reported sensitivity, specificity, and positive and negative predictive values of 90%, 94%, 74%, and 98%, respectively, which compares favorably with the results obtained in this study.

Six of the 9 positive cervical specimens were positive by both DB and SB in this study. Two of 3 specimens positive by DB only had corresponding positive Papanicolaou smears. Although reports have suggested that biotinylated probes are not as sensitive as the 32P-labeled probes in the DB procedure, they appear to have equal sensitivity and specificity in the SB procedure. The remaining specimen that was positive by DB for types 31/33/35 and SB negative had a corresponding negative Papanicolaou smear.

Only 11/21 (52.4%) of the hybridization and cervical biopsy histology results were concordant. Seven of the remaining histology results were positive, even though the HPV DNA results were negative. This may reflect a lack of sensitivity on the part of the DB and SB assays or perhaps a sampling variation. Due to the limited number of biopsies, we were unable to draw any conclusions.

Although SB is considered the gold standard based on its greater sensitivity and specificity, when the results from the Oncor SB using 32P-labeled probes were compared with the ViraPap DB, it was reported to be less sensitive. Perhaps this observation was due to a loss of DNA
during the extraction and transfer steps of the SB procedure, particularly if only a small quantity of DNA was present in the specimen. Whether our findings are consistent with Bartholoma et al. and Kviat et al. or the 3 specimens that were positive by DB were, in fact, true positives cannot be determined with certainty. These specimens will be tested by a hybrid-capture chemiluminescent procedure (Digene Diagnostics, Inc.) (manuscript in preparation), a new 6-h procedure for detecting HPV DNA.

Bartholoma et al. compared the results from cervical specimens using the Oncor SB 32P-labeled probes, and the ViraPap DB. Seventy-four percent (37/50 specimens) compared favorably. The discrepancies resulted from a lack of detection of HPV types 31/33/35 by SB. Eight specimens were positive by DB for types 31/33/35 and negative by the Oncor SB. One of these DB-positive specimens, which gave bands by SB, may have represented a cross-reaction, e.g., HPV type 16 shares a region of DNA homology with type 31.

In this study, the 3 discrepant specimens were deemed adequate during the microscopic-quality assessment procedure. The sampling variations were minimized or eliminated by combining the paired specimens and then distributing them in equal volumes for DB and SB testing. To avoid interobserver variation, each SB and DB test result was evaluated independently by 2 observers without prior clinical or Papanicolaou-smear information. A third individual was responsible for coding the specimens prior to testing. There was 100% concordance of interpretations by the observers.

Weintraub et al. compared the ViraType and cytology results and reported a concordance of 56% and a sensitivity and specificity of 48% and 77%, respectively. These results were similar to our findings, i.e., 84.2% concordance, 44.4% sensitivity, and 87.6% specificity, emphasizing the lack of predictability of the Papanicolaou smears for HPV infection. Although 19/169 Papanicolaou smears were reported as SIL-L, none was interpreted as SIL-H or CIS. Interestingly, 2 patients with previous normal Papanicolaou smears had smears showing squamous atypia and SIL-L. Both were positive for type 18 or 16/18. Infection with type 18 has been reported to occur in younger age groups (8–12 years old), cause a higher recurrence rate, and have the potential to rapidly progress to CIS within 1 year.

Two of the 13 specimens (15.4%) were multiply infected with HPV. One biopsy was positive for HPV types 6, 16, and 33 and the second biopsy was positive for types 6 and 16. Dual infections are not unusual and may represent exposure to multiple partners. Burmer et al. reported a rate of 12% of multiple infections in their patient population.

Our study did not support the observation that an early onset of sexual relations increases the risk of HPV infection. However, only 42/172 patients enrolled in this study had their first sexual relations between 13 and 16 years of age. The only risk factor identified in this study was the number of sexual partners. Finding an association with the number of sexual partners is remarkable, considering the sample size.

In conclusion, the detection of HPV and identification of the specific type may have significant diagnostic and prognostic implications. To date, these viruses cannot be isolated in cell culture due to the requirement for cell differentiation in a productive or permissive infection, nor can serology be employed to provide a laboratory diagnosis. More sophisticated molecular diagnostic techniques have been developed utilizing DNA hybridization in order to detect this unique group of viruses.

Several testing formats are currently available for HPV DNA detection. The test method that is chosen should be easy to use, involve a reasonable turnaround time and minimal hands-on, employ a non-radioisotopic label for the probes, and provide excellent sensitivity, specificity, and predictive values, all at a reasonable cost. Although neither of the kits employed in this study fulfills all of these requirements, both methods have acceptable sensitivity, specificity, and predictive values when compared with cytology. Each kit has advantages and disadvantages. Both kits are designed for batching specimens due to the cost associated with the reagents, as well as the hands-on and turnaround time from start to finish of each run. With the implementation of stringent cost-containment programs throughout the country and decreases in laboratory staff in many hospitals, HPV testing may be considered in the following select cases: 1) history of another sexually transmitted disease, 2) equivocal Papanicolaou smear, 3) history of multi-

---

**EVALUATION OF TWO HPV TESTS**

**HALSTEAD ET AL.**
ple sexual partners, and 4) immunocompromised status.

ACKNOWLEDGMENTS

The authors express their thanks to James Dorsey, M.D., and Arthur Fetzer, M.D., for providing most of the specimens; Sandra Todd, Microbiology/Virology Division, for help in coding the specimens; Kathleen Moser, B.A., Research Department, for assistance in editing and preparation of the figures; and Lehigh Valley Hospital for the use of their facilities. A special thank you to Digene Diagnostics, Inc., and Oncor, Inc., for their technical support and for the supply of some of the kits for testing.

REFERENCES

Submit your manuscripts at
http://www.hindawi.com